Currently, no Treg-based therapies are approved. The regulatory T-cells (Tregs) sector across the seven major markets (7MM) ...

The California Institute for Regenerative Medicine (CIRM) has given $8m to biotechnology company Tr1X to support its trial of ...

Nektar Therapeutics’s NKTR share price has surged by 18.21%, which has investors questioning if this is right time to sell.

The female sex hormone estrogen, along with progesterone, appears to underlie a fundamental difference in how males and ...

Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered ...

Tr1X awarded $8 million CIRM grant to support TRX103 phase 1/2a trial for graft-versus-host disease: San Diego Monday, April 7, 2025, 11:00 Hrs [IST] Tr1X, Inc. (Trix), a clinical ...